Sucampo Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SCMP)

$17.95 0.05 (0.28 %)
(As of 01/24/2018 04:15 AM ET)
Previous Close$17.90
Today's Range$17.90 - $18.02
52-Week Range$9.30 - $18.75
Volume4.22 million shs
Average Volume3.56 million shs
Market Capitalization$838.30 million
P/E Ratio-5.36
Dividend YieldN/A
Beta1.45

About Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals logoSucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

Receive SCMP News and Ratings via Email

Sign-up to receive the latest news and ratings for SCMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:SCMP
CUSIP86490910
Phone+1-301-9613400

Debt

Debt-to-Equity Ratio7.37%
Current Ratio5.11%
Quick Ratio4.46%

Price-To-Earnings

Trailing P/E Ratio-5.35820895522388
Forward P/E Ratio16.03
P/E Growth5.04

Sales & Book Value

Annual Sales$230.06 million
Price / Sales3.68
Cash Flow$2.41 per share
Price / Cash7.45
Book Value$3.60 per share
Price / Book4.99

Profitability

Trailing EPS($3.35)
Net Income$18.48 million
Net Margins-60.24%
Return on Equity74.58%
Return on Assets16.85%

Miscellaneous

Employees139
Outstanding Shares47,170,000

Sucampo Pharmaceuticals (NASDAQ:SCMP) Frequently Asked Questions

What is Sucampo Pharmaceuticals' stock symbol?

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

How were Sucampo Pharmaceuticals' earnings last quarter?

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) issued its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of $0.25 by $0.02. The biopharmaceutical company had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The firm's quarterly revenue was up 5.9% on a year-over-year basis. During the same period last year, the business posted $0.30 earnings per share. View Sucampo Pharmaceuticals' Earnings History.

When will Sucampo Pharmaceuticals make its next earnings announcement?

Sucampo Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Sucampo Pharmaceuticals.

What guidance has Sucampo Pharmaceuticals issued on next quarter's earnings?

Sucampo Pharmaceuticals updated its FY17 earnings guidance on Wednesday, November, 1st. The company provided earnings per share guidance of $1.10-1.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.01. The company issued revenue guidance of $250-255 million, compared to the consensus revenue estimate of $234.49 million.

Where is Sucampo Pharmaceuticals' stock going? Where will Sucampo Pharmaceuticals' stock price be in 2018?

9 brokerages have issued 12 month target prices for Sucampo Pharmaceuticals' stock. Their predictions range from $11.00 to $43.00. On average, they expect Sucampo Pharmaceuticals' share price to reach $24.00 in the next year. View Analyst Ratings for Sucampo Pharmaceuticals.

What are Wall Street analysts saying about Sucampo Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:

  • 1. Maxim Group analysts commented, "Sucampo’s stock has risen sharply in the past few weeks (from ~$10 to $16+) on no new fundamental news. However, a Bloomberg story has been circulating that the company may be entertaining suitors. We have no specific knowledge to confirm this, but do see an undervalued company that is generating free cash flow and has a strong (orphan) pipeline. Our last note (from 11/21) reviewed the R&D Day which focused on two key pipeline products, VTS-270 (Neeman Pick Disease) and CPP-1X/sulindac (Familial Adenomatous Polyposis )." (12/7/2017)
  • 2. According to Zacks Investment Research, "Sucampo is focused on expanding Amitiza’s label and penetrating new markets. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Also, through the agreement with Cancer Prevention Pharmaceuticals, Sucampo acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, dependence of Sucampo on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. A decline in Amitiza's sales will adversely impact the top line. Moreover, it had its share of pipeline setbacks. Shares of the company have underperformed the industry. Estimates have remained stable ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in the recent quarters." (10/17/2017)
  • 3. Jefferies Group LLC analysts commented, "Post the Q4 results and guidance we have revisited our assumptions and are making two changes to our model reflecting ' 1) likely Amitiza mandated price erosion in Japan and 2) our switch projections for the alternative formulation of Amitiza. We also fine-tune our FY17 revs and EPS estimates. We continue to view potential business development/M&A as critical to the longer term outlook given the finite life of Amitiza and await mgt's plans." (3/17/2017)
  • 4. Mizuho analysts commented, "We reiterate our Buy rating and $16 PT into the 4Q:16 print on March 8. The near-term Amitiza outlook remains favorable in both the U.S. and Japanese markets, which we believe may support additional optionality for the company in front of its 2021 patent cliff." (3/6/2017)

Are investors shorting Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals saw a increase in short interest in December. As of December 15th, there was short interest totalling 6,734,908 shares, an increase of 43.7% from the November 30th total of 4,686,290 shares. Based on an average trading volume of 3,643,384 shares, the days-to-cover ratio is presently 1.8 days. Currently, 27.6% of the company's stock are sold short.

Who are some of Sucampo Pharmaceuticals' key competitors?

Who are Sucampo Pharmaceuticals' key executives?

Sucampo Pharmaceuticals' management team includes the folowing people:

  • Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer (Age 47)
  • Peter P. Pfreundschuh CPA, Chief Financial Officer (Age 48)
  • Max Donley, Executive Vice President of Global Human Resources, Information Technology and Strategy (Age 48)
  • Matthias Alder, Executive Vice President (Age 52)
  • Peter A. Kiener Ph.D., Chief Scientific Officer (Age 64)
  • Alex Driggs, General Counsel, Corporate Secretary (Age 41)
  • Peter Lichtlen M.D., Ph.D., Chief Medical Officer (Age 47)
  • John H. Johnson, Lead Independent Director (Age 58)
  • Paul R. Edick, Director (Age 62)
  • Daniel P. Getman Ph.D., Director (Age 59)

Who owns Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include ING GROEP NV (6.70%), ING GROEP NV (6.70%), LINDEN CAPITAL L.P. (5.10%), LINDEN CAPITAL L.P. (4.60%), Longfellow Investment Management Co. LLC (0.42%) and Schwab Charles Investment Management Inc. (0.40%). Company insiders that own Sucampo Pharmaceuticals stock include Andrew P Smith, Daniel P Getman, Jason Patrick Meyenburg, Jones W Bryan, Matthias Alder, Peter A Kiener, Peter Greenleaf and Sachiko Kuno. View Institutional Ownership Trends for Sucampo Pharmaceuticals.

Who sold Sucampo Pharmaceuticals stock? Who is selling Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. Company insiders that have sold Sucampo Pharmaceuticals company stock in the last year include Peter A Kiener and Sachiko Kuno. View Insider Buying and Selling for Sucampo Pharmaceuticals.

Who bought Sucampo Pharmaceuticals stock? Who is buying Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Longfellow Investment Management Co. LLC, Havens Advisors LLC, Bowling Portfolio Management LLC, Acadian Asset Management LLC and Bank of Montreal Can. Company insiders that have bought Sucampo Pharmaceuticals stock in the last two years include Jason Patrick Meyenburg and Jones W Bryan. View Insider Buying and Selling for Sucampo Pharmaceuticals.

How do I buy Sucampo Pharmaceuticals stock?

Shares of Sucampo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sucampo Pharmaceuticals' stock price today?

One share of Sucampo Pharmaceuticals stock can currently be purchased for approximately $17.95.

How big of a company is Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals has a market capitalization of $838.30 million and generates $230.06 million in revenue each year. The biopharmaceutical company earns $18.48 million in net income (profit) each year or ($3.35) on an earnings per share basis. Sucampo Pharmaceuticals employs 139 workers across the globe.

How can I contact Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals' mailing address is 805 King Farm Blvd Ste 550, ROCKVILLE, MD 20850-6162, United States. The biopharmaceutical company can be reached via phone at +1-301-9613400 or via email at [email protected]


MarketBeat Community Rating for Sucampo Pharmaceuticals (SCMP)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  211 (Vote Underperform)
Total Votes:  465
MarketBeat's community ratings are surveys of what our community members think about Sucampo Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sucampo Pharmaceuticals (NASDAQ:SCMP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.442.782.672.83
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.00$23.56$17.67$17.17
Price Target Upside: 33.70% upside40.63% upside46.61% upside75.17% upside

Sucampo Pharmaceuticals (NASDAQ:SCMP) Consensus Price Target History

Price Target History for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals (NASDAQ:SCMP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2018MizuhoReiterated RatingNeutral -> Neutral$14.00 -> $18.00LowView Rating Details
1/2/2018Leerink SwannReiterated RatingOutperform -> Market Perform$15.00LowView Rating Details
1/1/2018Maxim GroupDowngradeHoldLowView Rating Details
12/26/2017B. RileyDowngradeBuy -> Neutral$18.00LowView Rating Details
12/19/2017InstinetInitiated CoverageBuy$43.00HighView Rating Details
12/18/2017NomuraInitiated CoverageBuy -> Buy$43.00HighView Rating Details
8/3/2017Roth CapitalSet Price TargetBuy$30.00MediumView Rating Details
5/4/2017Jefferies GroupLower Price TargetHold$13.00 -> $11.00MediumView Rating Details
3/10/2017WallachBeth CapitalLower Price TargetBuy$20.00 -> $15.00LowView Rating Details
9/7/2016Northland SecuritiesInitiated CoverageOutperform$15.00N/AView Rating Details
5/4/2016GuggenheimReiterated RatingBuy$29.00N/AView Rating Details
(Data available from 1/24/2016 forward)

Earnings

Sucampo Pharmaceuticals (NASDAQ:SCMP) Earnings History and Estimates Chart

Earnings by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals (NASDAQ SCMP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018$0.33N/AView Earnings Details
11/1/2017Q3 2017$0.25$0.27$58.05 million$61.27 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.22$0.28$56.44 million$59.90 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.28$0.23$54.15 million$56.30 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.48$0.68$66.00 million$73.00 millionViewListenView Earnings Details
11/9/2016Q316$0.26$0.28$51.30 million$57.90 millionViewListenView Earnings Details
8/3/2016Q216$0.22$0.23$48.33 million$52.00 millionViewListenView Earnings Details
5/4/2016Q116$0.19$0.21$44.11 million$47.20 millionViewListenView Earnings Details
3/8/2016Q415$0.19$0.43$42.72 million$55.40 millionViewListenView Earnings Details
11/4/2015Q315$0.18$0.16$36.18 million$33.50 millionViewListenView Earnings Details
8/5/2015Q215$0.15$0.21$31.90 million$34.90 millionViewListenView Earnings Details
5/6/2015Q114$0.14$0.14$30.19 million$29.50 millionViewListenView Earnings Details
3/4/2015Q413$0.17$0.21$37.23 million$37.80 millionViewListenView Earnings Details
11/6/2014Q313$0.04$0.03$26.11 million$31.50 millionViewListenView Earnings Details
8/5/2014Q213$0.03$0.04$24.06 million$24.10 millionViewListenView Earnings Details
5/7/2014Q113$0.04$0.02$24.19 million$22.20 millionViewListenView Earnings Details
2/26/2014Q4($0.04)$0.06$22.75 million$24.50 millionViewListenView Earnings Details
11/5/2013Q3 2013($0.03)$0.09ViewN/AView Earnings Details
8/8/2013Q2 2013$0.11$0.14ViewN/AView Earnings Details
5/7/2013Q1 2013($0.09)($0.08)ViewN/AView Earnings Details
3/13/2013Q4 2012$0.12$0.32$32.21 million$34.90 millionViewListenView Earnings Details
11/8/2012Q3 2012($0.07)($0.14)ViewN/AView Earnings Details
8/7/2012Q2 2012($0.02)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.05)ViewN/AView Earnings Details
3/13/2012Q4 2011($0.11)ViewN/AView Earnings Details
11/3/2011Q3 2011($0.10)ViewN/AView Earnings Details
8/4/2011Q2 2011($0.22)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.17)ViewN/AView Earnings Details
3/3/2011Q4 2010($0.01)($0.15)ViewN/AView Earnings Details
11/3/2010Q3 2010($0.05)$0.06ViewN/AView Earnings Details
8/5/2010Q2 2010($0.01)($0.05)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.01)ViewN/AView Earnings Details
3/15/2010Q4 2009$0.02$0.03ViewN/AView Earnings Details
8/6/2009Q2 2009($0.01)($0.01)ViewN/AView Earnings Details
5/7/2009Q1 2009$0.02($0.04)ViewN/AView Earnings Details
2/19/2009Q4 2008($0.06)($0.07)ViewN/AView Earnings Details
11/12/2008Q3 2008$0.01($0.06)ViewN/AView Earnings Details
8/14/2008Q2 2008$0.62$0.71ViewN/AView Earnings Details
5/8/2008Q1 2008($0.01)$0.01ViewN/AView Earnings Details
3/11/2008Q4 2007($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Sucampo Pharmaceuticals (NASDAQ:SCMP) Earnings Estimates

2018 EPS Consensus Estimate: $1.15
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.26$0.26$0.26
Q2 20181$0.24$0.24$0.24
Q3 20181$0.28$0.28$0.28
Q4 20181$0.37$0.37$0.37
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Sucampo Pharmaceuticals (NASDAQ:SCMP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sucampo Pharmaceuticals (NASDAQ SCMP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.13%
Institutional Ownership Percentage: 64.62%
Insider Trades by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals (NASDAQ SCMP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/7/2017Peter A KienerInsiderSell50,000$16.50$825,000.0052,023View SEC Filing  
9/11/2017Sachiko KunoMajor ShareholderSell1,000,000$12.00$12,000,000.00View SEC Filing  
9/6/2017Jason Patrick MeyenburgInsiderBuy4,000$12.13$48,520.0030,228View SEC Filing  
8/4/2017Jones W BryanInsiderBuy4,700$10.60$49,820.004,700View SEC Filing  
11/29/2016Daniel P GetmanDirectorSell20,000$16.86$337,200.0016,201View SEC Filing  
11/29/2016Peter GreenleafCEOSell200,000$16.84$3,368,000.00120,054View SEC Filing  
11/28/2016Matthias AlderEVPSell150,000$16.00$2,400,000.0029,449View SEC Filing  
11/15/2016Andrew P SmithCFOSell1,766$15.58$27,514.28348View SEC Filing  
8/28/2015Daniel P. GetmanDirectorSell30,000$28.14$844,200.00View SEC Filing  
7/20/2015Thomas J KnappInsiderSell64,528$23.43$1,511,891.04View SEC Filing  
3/12/2015William AshtonDirectorSell55,762$17.55$978,623.10View SEC Filing  
3/11/2015Anthony C CelesteDirectorSell65,966$17.34$1,143,850.44View SEC Filing  
12/16/2014Cary J ClaiborneCFOSell50,000$12.91$645,500.00View SEC Filing  
12/15/2014Cary J ClaiborneCFOSell7,100$12.89$91,519.00View SEC Filing  
8/7/2014Sachiko KunoMajor ShareholderSell181,727$6.28$1,141,245.56View SEC Filing  
8/4/2014Ryuji UenoMajor ShareholderSell140,873$6.02$848,055.46View SEC Filing  
7/31/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/30/2014S&R Technology Holdings, LlcMajor ShareholderSell300$6.25$1,875.00View SEC Filing  
7/25/2014Ryuji UenoMajor ShareholderSell16,155$6.26$101,130.30View SEC Filing  
7/23/2014Ryuji UenoMajor ShareholderSell5,845$6.29$36,765.05View SEC Filing  
7/22/2014S&R Technology Holdings, LlcMajor ShareholderSell2,500$6.25$15,625.00View SEC Filing  
7/21/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/18/2014S&R Technology Holdings, LlcMajor ShareholderSell15,000$6.27$94,050.00View SEC Filing  
4/29/2014S&R Technology Holdings, Llcmajor shareholderSell113,600$6.65$755,440.0022,820,802View SEC Filing  
4/25/2014Sachiko Kunomajor shareholderSell118,700$6.69$794,103.0060,357View SEC Filing  
3/18/2014Gayle DolecekDirectorSell1,200$8.03$9,636.00View SEC Filing  
2/27/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
1/17/2014Ryuji UenoCEOSell360,000$10.36$3,729,600.00148,530View SEC Filing  
1/7/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
10/16/2013Sachiko KunoMajor ShareholderSell360,000$6.35$2,286,000.00View SEC Filing  
9/18/2013Ryuji UenoCEOSell38,462$5.69$218,848.78148,530View SEC Filing  
9/3/2013Ryuji UenoCEOSell38,462$5.59$215,002.58148,530View SEC Filing  
8/19/2013Ryuji UenoCEOSell38,462$6.04$232,310.48148,530View SEC Filing  
8/6/2013Sachiko Kunomajor shareholderSell38,462$6.21$238,849.0260,357View SEC Filing  
7/24/2013Ryuji UenoCEOSell38,462$6.52$250,772.24View SEC Filing  
7/9/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.48$249,233.76View SEC Filing  
6/24/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.61$254,233.82View SEC Filing  
6/10/2013Sachiko KunoMajor ShareholderSell38,462$7.29$280,387.98View SEC Filing  
5/28/2013Ryuji UenoCEOSell38,462$8.79$338,080.98View SEC Filing  
5/21/2013Cary J ClaiborneCFOSell4,640$9.52$44,172.80View SEC Filing  
5/20/2013Stanley G MieleSVPSell6,400$9.60$61,440.00View SEC Filing  
5/16/2013Stanley G MieleSVPSell48,600$9.67$469,962.00View SEC Filing  
5/15/2013Timothy I MaudlinDirectorBuy32,870$9.82$322,783.40View SEC Filing  
5/13/2013Sachiko KunoMajor ShareholderSell38,462$9.27$356,542.74View SEC Filing  
2/4/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$5.22$200,771.64View SEC Filing  
12/26/2012S&R Technology Holdings, LlcMajor ShareholderSell20,262$5.01$101,512.62View SEC Filing  
11/27/2012Sachiko KunoMajor ShareholderSell12,205$5.00$61,025.00View SEC Filing  
11/13/2012Sachiko KunoMajor ShareholderSell11,962$5.00$59,810.00View SEC Filing  
11/1/2012Sachiko KunoMajor ShareholderSell37,595$5.06$190,230.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sucampo Pharmaceuticals (NASDAQ SCMP) News Headlines

Source:
DateHeadline
SUCAMPO PHARMACEUTICALS (SCMP) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Sucampo Pharmaceuticals, Inc. for Potential Breaches of Fiduciary DutySUCAMPO PHARMACEUTICALS (SCMP) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Sucampo Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty
finance.yahoo.com - January 22 at 6:03 PM
Lifshitz & Miller LLP Announces Investigation of Advanced Micro Devices, Aflac Incorporated, DST Systems, Inc., Forum Merger Corporation, GoPro, Inc., Sucampo Pharmaceuticals, Inc. and ZAIS Group Holdings, Inc.Lifshitz & Miller LLP Announces Investigation of Advanced Micro Devices, Aflac Incorporated, DST Systems, Inc., Forum Merger Corporation, GoPro, Inc., Sucampo Pharmaceuticals, Inc. and ZAIS Group Holdings, Inc.
www.prnewswire.com - January 21 at 1:46 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Receives Average Recommendation of "Buy" from BrokeragesSucampo Pharmaceuticals, Inc. (SCMP) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 20 at 3:38 AM
$75.59 Million in Sales Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter$75.59 Million in Sales Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter
www.americanbankingnews.com - January 17 at 2:40 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Announce Earnings of $0.34 Per ShareSucampo Pharmaceuticals, Inc. (SCMP) Expected to Announce Earnings of $0.34 Per Share
www.americanbankingnews.com - January 15 at 9:14 PM
Aradigm's Bronchiectasis Candidate Has Negative FDA VoteAradigm's Bronchiectasis Candidate Has Negative FDA Vote
finance.yahoo.com - January 12 at 3:33 PM
Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?
finance.yahoo.com - January 12 at 11:23 AM
Sucampo Pharmaceuticals (SCMP) Cut to "Neutral" at UBS GroupSucampo Pharmaceuticals (SCMP) Cut to "Neutral" at UBS Group
www.americanbankingnews.com - January 7 at 8:37 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Post FY2019 Earnings of $1.79 Per ShareSucampo Pharmaceuticals, Inc. (SCMP) Expected to Post FY2019 Earnings of $1.79 Per Share
www.americanbankingnews.com - January 5 at 6:34 PM
Are Options Traders Betting on a Big Move in Sucampo (SCMP) Stock?Are Options Traders Betting on a Big Move in Sucampo (SCMP) Stock?
finance.yahoo.com - January 5 at 11:12 AM
Celsion's Phase I/II Cancer Study Initiation Gets FDA NodCelsion's Phase I/II Cancer Study Initiation Gets FDA Nod
finance.yahoo.com - January 5 at 11:12 AM
Omeros Inks Agreement With FDA for OMS721 Phase III TrialOmeros Inks Agreement With FDA for OMS721 Phase III Trial
finance.yahoo.com - January 4 at 11:17 AM
Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc - PR Newswire (press release)Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc - PR Newswire (press release)
www.prnewswire.com - January 2 at 8:51 PM
Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plcWolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc
finance.yahoo.com - January 2 at 11:10 AM
Sucampo Pharmaceuticals (SCMP) Rating Reiterated by Leerink SwannSucampo Pharmaceuticals (SCMP) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - January 2 at 8:48 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Announce Quarterly Sales of $75.59 MillionSucampo Pharmaceuticals, Inc. (SCMP) Expected to Announce Quarterly Sales of $75.59 Million
www.americanbankingnews.com - January 1 at 10:32 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc ... - PR Newswire (press release)SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc ... - PR Newswire (press release)
www.prnewswire.com - January 1 at 3:35 PM
Sucampo Pharmaceuticals (SCMP) Upgraded at ValuEngineSucampo Pharmaceuticals (SCMP) Upgraded at ValuEngine
www.americanbankingnews.com - January 1 at 11:22 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc. -- SCMPSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc. -- SCMP
finance.yahoo.com - January 1 at 11:07 AM
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Sucampo Pharmaceuticals, Inc. - SCMPSHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Sucampo Pharmaceuticals, Inc. - SCMP
finance.yahoo.com - December 29 at 10:51 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Sees Large Increase in Short InterestSucampo Pharmaceuticals, Inc. (SCMP) Sees Large Increase in Short Interest
www.americanbankingnews.com - December 29 at 1:58 AM
CORRECTING and REPLACING Investor Alert: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Sucampo Pharmaceuticals, Inc. to Mallinckrodt plc is Fair to ShareholdersCORRECTING and REPLACING Investor Alert: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Sucampo Pharmaceuticals, Inc. to Mallinckrodt plc is Fair to Shareholders
finance.yahoo.com - December 28 at 3:10 PM
Wired News - Mallinckrodt to Acquire Sucampo PharmaceuticalsWired News - Mallinckrodt to Acquire Sucampo Pharmaceuticals
finance.yahoo.com - December 28 at 8:53 AM
Mallinckrodt to Buy Sucampo Pharmaceuticals for About $840 MillionMallinckrodt to Buy Sucampo Pharmaceuticals for About $840 Million
www.wsj.com - December 27 at 6:11 PM
Mallinckrodt International Finance SA -- Moodys places Mallinckrodts ratings under review for downgrade following Sucampo announcementMallinckrodt International Finance SA -- Moody's places Mallinckrodt's ratings under review for downgrade following Sucampo announcement
finance.yahoo.com - December 27 at 6:11 PM
Analyst: Why The Sucampo Deal Is A Smart Move For MallinckrodtAnalyst: Why The Sucampo Deal Is A Smart Move For Mallinckrodt
finance.yahoo.com - December 27 at 6:11 PM
Analyst: Why The Sucampo (NASDAQ:SCMP) Deal Is A Smart Move ... - BenzingaAnalyst: Why The Sucampo (NASDAQ:SCMP) Deal Is A Smart Move ... - Benzinga
www.benzinga.com - December 27 at 1:07 PM
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Sucampo Pharmaceuticals, Inc. - SCMPSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Sucampo Pharmaceuticals, Inc. - SCMP
finance.yahoo.com - December 27 at 1:07 PM
Sucampo Pharma (SCMP) Deal Terms Substantially Undervalues Company, Worth $29/Share At Least - Nomura/Instinet - StreetInsider.comSucampo Pharma (SCMP) Deal Terms 'Substantially Undervalues' Company, Worth $29/Share At Least - Nomura/Instinet - StreetInsider.com
www.streetinsider.com - December 26 at 3:25 PM
Sucampo Pharmaceuticals (SCMP) Downgraded by B. RileySucampo Pharmaceuticals (SCMP) Downgraded by B. Riley
www.americanbankingnews.com - December 26 at 2:34 PM
Pre-Market Most Active for Dec 26, 2017 : SCMP, AAPL, CVG, SNI, MU, QQQ, TVIX, BAC, GE, TEVA, TWTR, FCX - NasdaqPre-Market Most Active for Dec 26, 2017 : SCMP, AAPL, CVG, SNI, MU, QQQ, TVIX, BAC, GE, TEVA, TWTR, FCX - Nasdaq
www.nasdaq.com - December 26 at 12:42 PM
Mallinckrodt (MNK) to Acquire Sucampo Pharmaceuticals (SCMP) for ~$1.2B - StreetInsider.comMallinckrodt (MNK) to Acquire Sucampo Pharmaceuticals (SCMP) for ~$1.2B - StreetInsider.com
www.streetinsider.com - December 26 at 12:42 PM
Mallinckrodt: Maybe Thisll Work?Mallinckrodt: Maybe This'll Work?
finance.yahoo.com - December 26 at 12:42 PM
Will a Sucampo Acquisition Get Mallinckrodt Back on Track?Will a Sucampo Acquisition Get Mallinckrodt Back on Track?
finance.yahoo.com - December 26 at 12:42 PM
What Does Sucampo Pharmaceuticals Inc’s (NASDAQ:SCMP) Share Price Indicate?What Does Sucampo Pharmaceuticals Inc’s (NASDAQ:SCMP) Share Price Indicate?
finance.yahoo.com - December 26 at 12:42 PM
Mid-Morning Market Update: Markets Mostly Lower; Mallinckrodt To Buy Sucampo Pharmaceuticals For $18/ShareMid-Morning Market Update: Markets Mostly Lower; Mallinckrodt To Buy Sucampo Pharmaceuticals For $18/Share
feeds.benzinga.com - December 26 at 11:39 AM
Sucampo Pharmaceuticals (SCMP) Downgraded by Maxim GroupSucampo Pharmaceuticals (SCMP) Downgraded by Maxim Group
www.americanbankingnews.com - December 26 at 11:28 AM
Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 BillionMallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
www.prnewswire.com - December 26 at 7:37 AM
A Peek Into The Markets: U.S. Stock Futures Down; Mallinckrodt To Acquire Sucampo PharmaceuticalsA Peek Into The Markets: U.S. Stock Futures Down; Mallinckrodt To Acquire Sucampo Pharmaceuticals
feeds.benzinga.com - December 26 at 7:37 AM
Analysts’ Recommendations for Sucampo PharmaceuticalsAnalysts’ Recommendations for Sucampo Pharmaceuticals
finance.yahoo.com - December 21 at 3:39 PM
Sucampo Pharmaceuticals’ Amitiza: Its Performance in 2017Sucampo Pharmaceuticals’ Amitiza: Its Performance in 2017
finance.yahoo.com - December 21 at 3:39 PM
Sucampo Pharmaceuticals (SCMP) Now Covered by InstinetSucampo Pharmaceuticals (SCMP) Now Covered by Instinet
www.americanbankingnews.com - December 19 at 6:08 PM
Regeneron in Strategic Immuno-Oncology Collaboration With ISARegeneron in Strategic Immuno-Oncology Collaboration With ISA
finance.yahoo.com - December 19 at 11:27 AM
Sucampo Pharmaceuticals (SCMP) Now Covered by NomuraSucampo Pharmaceuticals (SCMP) Now Covered by Nomura
www.americanbankingnews.com - December 18 at 5:35 PM
Sucampo Pharmaceuticals (SCMP) Upgraded to "Strong-Buy" by BidaskClubSucampo Pharmaceuticals (SCMP) Upgraded to "Strong-Buy" by BidaskClub
www.americanbankingnews.com - December 17 at 3:46 PM
Stock Traders Purchase Large Volume of Put Options on Sucampo Pharmaceuticals (SCMP)Stock Traders Purchase Large Volume of Put Options on Sucampo Pharmaceuticals (SCMP)
www.americanbankingnews.com - December 17 at 1:06 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Post Quarterly Sales of $75.59 MillionSucampo Pharmaceuticals, Inc. (SCMP) Expected to Post Quarterly Sales of $75.59 Million
www.americanbankingnews.com - December 14 at 4:52 AM
$0.34 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter$0.34 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter
www.americanbankingnews.com - December 12 at 9:30 PM
Peter A. Kiener Sells 50,000 Shares of Sucampo Pharmaceuticals, Inc. (SCMP) StockPeter A. Kiener Sells 50,000 Shares of Sucampo Pharmaceuticals, Inc. (SCMP) Stock
www.americanbankingnews.com - December 11 at 8:50 PM
Sucampo Pharmaceuticals (SCMP) Raised to "Buy" at BidaskClubSucampo Pharmaceuticals (SCMP) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - December 11 at 12:52 AM

SEC Filings

Sucampo Pharmaceuticals (NASDAQ:SCMP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sucampo Pharmaceuticals (NASDAQ:SCMP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sucampo Pharmaceuticals (NASDAQ SCMP) Stock Chart for Wednesday, January, 24, 2018

Loading chart…

This page was last updated on 1/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.